RNS Number : 3123EAvacta Group PLC28 October 2022


28 October 2022

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Block Listing Six Monthly Return

Avacta Group plc (AIM: AVCT), a clinical stage oncology company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, todaymakes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:

Avacta Group plc

Name of scheme:

EMI scheme

Period of return:

From:

28 April 2022


27 October 2022

Balance of unallotted securities under scheme(s) from previous return:

750,000

Plus:The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less:Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

290,500

Equals:Balance under scheme(s) not yet issued/allotted at end of period:

459,500






Name of applicant:

Avacta Group plc

Name of scheme:

LTIP scheme

Period of return:

From:

28 April 2022


27 October 2022

Balance of unallotted securities under scheme(s):

1,250,000

Plus:The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less:Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

790,813

Equals:Balance under scheme(s) not yet issued/allotted at end of period:

459,187






Name of contact:

Tony Gardiner, Company Secretary

Telephone number of contact:

+ 44 (0)1904 217070

Ends-

For further information from Avacta Group plc, please contact:

Avacta Group plc

Alastair Smith, Chief Executive Officer

Tony Gardiner, Chief Financial Officer

Michael Vinegrad, Group Communications Director

Tel: +44 (0) 1904 21 7070

www.avacta.com

Stifel Nicolaus Europe Limited(Nomad and Broker)

Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Dhiren Suares / William Palmer-Brown

Tel: +44 (0) 207 710 7600

www.stifel.com

FTI Consulting (Financial Media and IR)

Simon Conway / Alex Shaw/George Kendrick

Tel: +44(0) 203 727 1000

[email protected]

Zyme Communications(Trade and Regional Media)

Lily Jeffery

Tel: +44 (0)7891 477 378

[email protected]

About Avacta Group plc -https://www.avacta.com

Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies.

The Affimer® platform is an alternative to antibodies and is derived from a small human protein. Affimer technology has been designed to address many of the negative issues of antibodies, principally: the time taken to generate new antibodies, the reliance on an animal's immune response; poor specificity in many cases; in addition to, the complexity and high cost of manufacture. Despite these shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, which are worth in excess of $100bn.

Avacta's pre|CISION™ targeted chemotherapy platform is designed to selectively release active chemotherapy in FAP rich tumour tissue to limit the systemic exposure that causes damage to healthy tissues, and thereby aims to improve the overall safety and therapeutic potential of these powerful anti-cancer treatments.

The Avacta Group comprises two divisions: The therapeutics development activities are based in London, UK and a separate diagnostics business unit is based in Wetherby, UK. The Group is generating near-term revenues from Affimer® reagents for diagnostics, bioprocessing and research.

Avacta's Diagnostics Division is developing an in-house pipeline of Affimer-based diagnostic assays, including the AffiDX® SARS-CoV-2 Lateral Flow Rapid Antigen Test, and works with partners world-wide to develop bespoke Affimer® reagents for third party products.

Avacta's Therapeutics Division is working to generate more tolerable and durable treatments for oncology patients who do not respond to existing therapies. By combining its two proprietary platforms the Group is building a wholly owned pipeline of clinically differentiated cancer therapies. In 2021 Avacta transitioned to become a clinical stage biopharmaceutical company, when it commenced a phase I trial in patients with locally advanced or metastatic selected solid tumours. The study was a first-in-human, open label, dose-escalation and expansion study of the Group's lead pre|CISION™ prodrug, AVA6000 (a pro-doxorubicin).

Avacta has established drug development partnerships with pharma and biotech, including a multi-target deal with LG Chem worth up to $400m, a joint venture in South Korea with Daewoong Pharmaceutical focused on cell and gene therapies incorporating Affimer immune-modulators and a recent license agreement with Point Biopharma for them to develop radiopharmaceuticals based on the pre|CISION™ platform.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. ENDBLRPPGCGUUPPUQM

==